FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry and represents pharmaceutical composition for treating gastroesophageal reflux disease, containing at least one proton pump inhibitor and at least one probiotic, wherein the proton pump inhibitor is taken in the amount of 0.05-25 wt % in the composition; and the probiotic is taken in the amount of 10-95 wt %; additive agents up to 100 wt %.
EFFECT: provided preventing Hpylori translocation, avoiding the necessity of Hpylori detection and antibacterial course of eradication, higher safety of the prolonged therapy with the proton pump inhibitors and avoided gastric mucosa atrophy, and a risk of gastric cancer.
5 cl, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF PROTON PUMP INHIBITOR AND PREBIOTIC FOR TREATING GASTRIC AND DUODENAL ULCERS | 2009 |
|
RU2410100C2 |
| METHOD FOR ANTI-HELICOBACTER THERAPY OF STOMACH AND DUODENUM | 2013 |
|
RU2537140C1 |
| METHOD FOR TREATMENT OF EXCESS BACTERIAL GROWTH IN SMALL INTESTINE IN PATIENTS WITH TYPE 2 DIABETES IN COMBINATION WITH GASTRODUODENAL HELICOBACTERIOSIS | 2017 |
|
RU2674447C1 |
| METHOD FOR TREATING EROSIVE FORM OF GASTROESOPHAGEAL REFLUX DISEASE IN PATIENTS PUT ON CHEMOTHERAPY | 2017 |
|
RU2667651C1 |
| METHOD FOR TREATING HELICOBACTER PYLORI-ASSOCIATED ULCEROUS GASTRIC AND DUODENAL DISEASE | 2006 |
|
RU2308949C1 |
| METHOD FOR PREDICTION OF PRECANCER DISEASES OF STOMACH | 2019 |
|
RU2706118C1 |
| TREATMENT OF INFLAMMATORY GASTROINTESTINAL DISEASED ASSOCIATED WITH HELICOBACTER PYLORI | 2004 |
|
RU2278682C2 |
| METHOD FOR HELICOBACTER PYLORI ERADICATION OF GASTRODUODENAL ZONE | 2014 |
|
RU2545687C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING RABEPRAZOLE AND METHOD FOR PRODUCING IT | 2014 |
|
RU2554735C1 |
| METHOD OF ASSESSING THE PROBABILITY OF ATROPHIC GASTRITIS IN PATIENTS WITH CHRONIC CORONARY HEART DISEASE | 2022 |
|
RU2806066C2 |
